6/3/2019 | DD | Orexigen Therapeutics amended liquidation plan effective as of May 31
|
5/31/2019 | DD | Orexigen Therapeutics records $31,000 loss from operations for April
|
5/17/2019 | DD | Orexigen Therapeutics amended plan of liquidation confirmed by court
|
4/30/2019 | DD | Orexigen Therapeutics posts $708,000 loss from operations for March
|
4/2/2019 | DD | Orexigen Therapeutics posts $1.45 million operating loss for February
|
3/27/2019 | DD | Orexigen wins interim OK of disclosure statement; plan hearing May 17
|
3/7/2019 | DD | Orexigen Therapeutics files plan of liquidation, disclosure statement
|
3/4/2019 | DD | Orexigen Therapeutics posts $1.45 million operating loss for January
|
1/30/2019 | DD | Orexigen Therapeutics posts $175,000 December operating loss, no sales
|
12/14/2018 | DD | Orexigen Therapeutics posts $239,000 November operating loss
|
12/3/2018 | DD | Orexigen Therapeutics posts $79,000 October operating loss, no sales
|
11/27/2018 | DD | Orexigen agreement party, subsidiary appeal fund entitlement ruling
|
11/13/2018 | DD | Court rules Orexigen agreement party not entitled to disputed funds
|
10/31/2018 | DD | Orexigen Therapeutics posts $526,000 September loss from operations
|
10/1/2018 | DD | Orexigen Therapeutics records $81,000 loss from operations for August
|
8/30/2018 | DD | Orexigen Therapeutics records $2.08 million operating loss for July
|
7/31/2018 | DD | Orexigen completes $73.5 million sale; directors and officers resign
|
7/30/2018 | DD | Orexigen Therapeutics records $1.72 million operating loss for June
|
7/13/2018 | DD | Orexigen granted exclusivity extension to negotiate and confirm plan
|
7/3/2018 | DD | Orexigen Therapeutics marks $3.97 million operating loss for May
|
6/28/2018 | DD | Orexigen Therapeutics $75 million sale of assets approved by court
|
6/27/2018 | DD | Orexigen seeks exclusivity extension to negotiate and confirm plan
|
6/22/2018 | DD | Orexigen cancels auction, to seek approval of $75 million asset sale
|
5/30/2018 | DD | Orexigen Therapeutics marks $7.21 million April loss from operations
|
5/18/2018 | DD | Orexigen $3.67 million McKesson receivable settlement OK’d by court
|
5/11/2018 | DD | Orexigen to get $3.67 million under McKesson receivable settlement
|
5/4/2018 | DD | Orexigen marks $1.33 million operating loss for March 12 to March 31
|
4/23/2018 | DD | Orexigen asset sale procedures OK’d; $75 million lead bid received
|
4/13/2018 | DD | Orexigen gets final approval of $70.35 million DIP financing package
|
4/3/2018 | DD | Orexigen Therapeutics announces Nasdaq decides to delist company stock
|
3/28/2018 | DD | Orexigen Therapeutics official unsecured creditors committee appointed
|
3/16/2018 | BKCVDDEMHY | Prospect News reports five new defaults for week of March 8-March 14
|
3/13/2018 | DD | Orexigen wins interim approval to access to $15 million of financing
|
3/12/2018 | CVDD | Orexigen files for Chapter 11, plans to hold auction for assets
|